Letter | Published:

Inhibition of monoamine oxidase B in the brains of smokers

Naturevolume 379pages733736 (1996) | Download Citation

Subjects

Abstract

THE massive health problem associated with cigarette smoking is exacerbated by the addictive properties of tobacco smoke and the limited success of current approaches to cessation of smoking1. Yet little is known about the neuropharmacological actions of cigarette smoke that contribute to smoking behaviour, or why smoking is so prevalent in psychiatric disorders2 and is associated with a decreased risk of Parkinson's disease3. Here we report that brains of living smokers show a 40% decrease in the level of monoamine oxidase B (MAO B; EC 1.4.3.4) relative to non-smokers or former smokers. MAO B is involved in the breakdown of dopamine, a neurotransmitter implicated in reinforcing and motivating behaviours as well as movement. MAO B inhibition is therefore associated with enhanced activity of dopamine4, as well as with decreased production of hydrogen peroxide, a source of reactive oxygen species5. We propose that reduction of MAO B activity may synergize with nicotine to produce the diverse behavioural and epidemiological effects of smoking.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Henningfield, J. E., Schuh, L. M. & Jarvik, M. E. in Psychopharmacology, the Fourth Generation of Progress (eds Bloom, F. W. & Kupfer, D. J.) Ch. 147, 1715–1729 (Raven, New York 1995).

  2. 2

    Hughes, J. R., Hatsukama, D. K., Mitchell, J. E. & Dahlgren, L. A. Am. J. Psychiatry 143, 993–997 (1986).

  3. 3

    Morens, D. M., Grandinetti, A., Reed, D., White, L. R. & Ross, G. W. Neurology 45, 1041–1051 (1995).

  4. 4

    Berry, M. D., Juorio, A. V. & Paterson, I. A. Prog. Neurobiol. 42, 375–391 (1994).

  5. 5

    Reiter, R. J. FASEB J. 9, 526–533 (1995).

  6. 6

    Fowler, J. S. et al. J. Neurochem. 51, 1524–1534 (1988).

  7. 7

    Fowler, J. S. et al. J. nucl. Med. 36, 1255–1262 (1995).

  8. 8

    Patlak, C. S., Blasberg, R. G. & Fenstermacher, J. D. J. cereb. Blood Flow Metab. 3, 1–7 (1983).

  9. 9

    Yamashita, K., Kobayashi, S., Yamaguchi, S., Kitani, M. & Tsunematsu, T. Gerontology 34, 199–204 (1988).

  10. 10

    Wang, G.-J., Volkow, N. D., Wolf, A. P., Brodie, J. D. & Hitzemann, R. J. J. nucl. Med. 35, 1457–1466 (1994).

  11. 11

    Stapleton, J. M. et al. National Institute on Drug Abuse Res Monogr. Ser. Vol. 132, 106 (Department of Health and Human Services, Washington DC, 1993).

  12. 12

    Riederer, P. & Youdim, M. B. H. J. Neurochem. 46, 1359–1365 (1986).

  13. 13

    Oreland., L., Fowler, C. J. & Schalling, D. Life Sci. 29, 2511–2518 (1981).

  14. 14

    Norman, T. R., Chamberlain, K. G. & French, M. A. Psychiatry Res. 20, 199–205 (1987).

  15. 15

    Carr, L. A. & Rowell, P. P. Neuropharmacology 29, 311–314 (1990).

  16. 16

    Pavlin, R. & Sket, D. Farmacentski Vest. 44, 185–192 (1993).

  17. 17

    Yu, P. H. & Boulton, A. A. Life Sci. 41, 675–682 (1987).

  18. 18

    Carr, L. A. & Basham, J. K. Life Sci. 48, 1173–1177 (1991).

  19. 19

    Fowler, J. S. et al. Synapse 18, 86–93 (1994).

  20. 20

    Boulton, A. A., Yu, P. H. & Tipton, K. F. Lancet i 114–115 (1988).

  21. 21

    Yong, V. W. & Perry, T. L. J. neurol. Sci. 72, 265–272 (1986).

  22. 22

    Tetrud, J. W. & Langston, J. W. Science 245, 519–522 (1989).

  23. 23

    Tariot, P. N., Cohen, R. M., Sunderland, T., Weingartner, H. & Murphey, D, L. Psychopharmacology 91, 489–495 (1987).

  24. 24

    Knoll, J., Yen, T. T. & Miklya, I. Life Sci. 54, 1047–1057 (1994).

  25. 25

    Dluzen. D. E. & McDermott, J. L. J. neural Trans. 85, 145–156 (1991).

  26. 26

    Jackson, D. M. & Westlind-Danielsson, A. in Pharmacology and Therapeutics Vol. 64 (ed. Mitchelson, F.) 291–369 (Pergamon, UK, 1994).

  27. 27

    Di Chiara, G. & Imperato, A. Proc. natn. Acad. Sci. U.S.A. 85, 5274–5278 (1988).

  28. 28

    Paterson, I. A., Juorio, A. V., Berry, M. D. & Zhu, M. Y. J. Pharmacol. exp. Ther. 258, 1019–1026 (1991).

  29. 29

    Jossan, S. S., Sakurai, E. & Oreland, L. Biogenic Amines 4, 371–379 (1987).

  30. 30

    Dougherty. E. An Introduction to Morphological Image Processing (SPIE Optical Engineering Press, Bellingham, WA, 1992).

  31. 31

    Berlin, I. et al. Clin. Pharmac. Ther. 58, 444–452 (1995).

Download references

Author information

Author notes

  1. J. S. Fowler: To whom correspondence should be addressed

Affiliations

  1. Brookhaven National Laboratory, Upton, New York, 11973, USA

    • J. S. Fowler
    • , N. D. Volkow
    • , G.-J. Wang
    • , N. Pappas
    • , J. Logan
    • , R. MacGregor
    • , D. Alexoff
    • , C. Shea
    • , D. Schlyer
    • , A. P. Wolf
    • , D. Warner
    •  & R. Cilento
  2. Department of Psychiatry, State University at Stony Brook, Stony Brook, New York, 11794, USA

    • N. D. Volkow
    •  & I. Zezulkova
  3. the Chemistry Department, Brookhaven National Laboratory, Upton, New York, 11973, USA

    • J. S. Fowler

Authors

  1. Search for J. S. Fowler in:

  2. Search for N. D. Volkow in:

  3. Search for G.-J. Wang in:

  4. Search for N. Pappas in:

  5. Search for J. Logan in:

  6. Search for R. MacGregor in:

  7. Search for D. Alexoff in:

  8. Search for C. Shea in:

  9. Search for D. Schlyer in:

  10. Search for A. P. Wolf in:

  11. Search for D. Warner in:

  12. Search for I. Zezulkova in:

  13. Search for R. Cilento in:

Corresponding author

Correspondence to J. S. Fowler.

About this article

Publication history

Received

Accepted

Issue Date

DOI

https://doi.org/10.1038/379733a0

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.